PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER
Details
- Status
- Prescription
- First Approved
- 2025-04-03
- Routes
- INTRAVENOUS
- Dosage Forms
- POWDER
PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER Approval History
What PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER Treats
7 indicationsPIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER is approved for 7 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Intra-abdominal Infections
- Nosocomial Pneumonia
- Skin and Skin Structure Infections
- Female Pelvic Infections
- Community-Acquired Pneumonia
- Appendicitis
- Peritonitis
Drugs Similar to PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER FDA Label Details
ProIndications & Usage
FDA Label (PDF)Piperacillin and tazobactam for injection, for intravenous use is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older Nosocomial pneumonia in adult and pediatric patients 2 months of age and older Skin and skin structure infections in adults Female pelvic infections in adults Community-acquired pneumonia in adults To reduce the development of drug-resistant bacteria and maintain the effectiveness of Piperacillin and tazobac...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.